KRAS and Patent ductus arteriosus: We have recently demonstrated that advanced glycation end-products (AGEs) promote proliferation of human pancreatic ductal adenocarcinoma (PDA) cell lines and that exogenous AGE administration markedly accelerates invasive tumour development in a mouse model of Kras-driven PaC [10].